RVU312 / Ryvu Therap - LARVOL DELTA

Novel class of small molecule direct STING agonists as potential cancer immunotherapy (SITC 2018) - "Conclusions These data demonstrate potent, novel, nextgeneration small molecule STING agonists activating STING-dependent signaling in both mouse and human immune cells to promote potential antitumor immunity. The compounds show good selectivity and in vitro ADME properties enabling further development for systemic administration as a single agent or in combinatory cancer immunotherapies."

IO Biomarker • Oncology

Development and characterization of next generation small molecule STING agonists (SITC 2019) - "Selvita's STING agonists activate STING-dependent signaling in both mouse and human immune cells promoting anti-tumor immunity. Treatment with Selvita's STING agonists led to tumor growth inhibition by engagement of the immune cells. The compounds show good selectivity and in vitro ADME properties enabling development for systemic administration as a single agent or in combinations with immunotherapies or targeted agents."

IO Biomarker

Discovery and characterization of next-generation small molecule direct STING agonists (AACR 2019) - "These data demonstrate potent, novel, next-generation small molecule STING agonists activating STING-dependent signaling in both mouse and human immune cells to promote potential antitumor immunity. The compounds show good selectivity and in vitro ADME properties enabling further development for systemic administration as a single agent or in combinatory immunotherapies for cancer treatment."

IO Biomarker

Selvita to present data from multiple oncology programs at AACR 2019 Annual Meeting (PRNewswire) - "Selvita...announced that data from multiple Selvita oncology programs will be presented at the American Association for Cancer Research (AACR) Annual Meeting taking place March 29 to April 3, 2019, in Atlanta. Data presented will include results from the SEL120, CDK8 kinase inhibitor program as well as data from small-molecule STING agonist and dual A2A/A2B adenosine receptors antagonist programs."

Clinical data • Preclinical